Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (NCT06850623)
A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- HonorHealth Research Institute — Scottsdale, Arizona
- Stanford Cancer Center Palo Alto — Stanford, California
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology — Boston, Massachusetts
- Henry Ford Centre — Detroit, Michigan
- Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- Brown University Cancer Institute — Providence, Rhode Island
- CAMBRIDGE CANCER TRIALS CENTRE-Addenbrooke's Hospital — Cambridge, Cambridge
- Gary Weston Centre- Imperial College Healthcare- Du Cane Road — Hammersmith, London
- The Royal Marsden- Downs Road — Sutton, Surrey
📞 Contact the Study Coordinator
Phone: (480) 323-1364
Email: clinicaltrials@honorhealth.com, lzhao@honorhealth.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced Pancreatic Adenocarcinoma
- PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy — Los Angeles, California
- Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma — Houston, Texas
- Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer — Rochester, Minnesota
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery — New Brunswick, New Jersey
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer — Chicago, Illinois
- 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer — Duarte, California
Explore by condition: All Locally Advanced Pancreatic Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.